leadf
logo-loader
RNS
viewSkinBioTherapeutics PLC

SkinBioTherapeutics - Result of AGM

RNS Number : 0323K
SkinBioTherapeutics PLC
29 December 2020
 

29 December 2020

 

SkinBioTherapeutics plc

 

Results of AGM

 

SkinBioTherapeutics plc's (AIM: SBTX or the "Company") announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed.

 

 

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

 

 

Resolution

For & Discretionary

Against

Withheld



Number of votes

%

Number of votes

%

Number of votes

01

Ordinary resolution to receive and adopt the 2020 Financial Statements

56,163,552

 

100.00%

 

Nil

0.00%

Nil

02

Ordinary resolution to re-appoint Jeffreys Henry as auditors

56,163,552

 

100.00%

 

Nil

0.00%

Nil

03

Ordinary resolution to re-elect Stuart Ashman as a director

56,140,652

99.96%

22,900

0.04%

Nil

04

Ordinary resolution to re-elect Martin Hunt as a director

56,140,652

99.96%

22,900

0.04%

Nil

05

Ordinary resolution to re-elect Dr Cathy Prescott as a director

56,163,552

 

100.00%

 

Nil

0.00%

Nil

06

Ordinary resolution to re-elect Doug Quinn as a director

56,140,652

99.96%

22,900

0.04%

Nil

07

Ordinary resolution to authorise the directors to allot shares

56,107,097

99.90%

22,900

0.04%

33,555

08

Special resolution to authorise the directors to disapply pre-emption rights

55,896,449

99.52%

37,294

0.07%

229,809

09

Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment

55,897,801

99.53%

35,942

0.06%

229,809

 

 

 

 

 

For more information please contact:

 

SkinBioTherapeutics plc

Tel: +44 (0) 161 468 2760

Stuart Ashman, CEO

Doug Quinn, CFO


Cenkos Securities plc (Nominated Adviser & Broker)

Tel: +44 (0) 20 7397 8900

Giles Balleny, Max Gould (Corporate Finance)

Michael Johnson (Sales)


Instinctif Partners

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis

    SkinBio@instinctif.com

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK.  For more information, visit:www.skinbiotherapeutics.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGKKCBPBBDDOBB

Quick facts: SkinBioTherapeutics PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read